RT Journal Article
T1 Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
A1 Garcia-Alfonso, Pilar
A1 Chaves, Manuel
A1 Muñoz, Andrés
A1 Salud, Antonieta
A1 García-Gonzalez, Maria
A1 Grávalos, Cristina
A1 Massuti, Bartomeu
A1 González-Flores, Encarna
A1 Queralt, Bernardo
A1 López-Ladrón, Amelia
A1 Losa, Ferran
A1 Gómez, Maria Jose
A1 Oltra, Amparo
A1 Aranda, Enrique
K1 Capecitabine
K1 Irinotecan
K1 Camptothecin
K1 Bevacizumab
K1 Metastatic colorectal cancer
K1 Chemotherapy
K1 Protocolos de quimioterapia combinada antineoplásica
K1 Camptotecina
K1 Neoplasias colorrectales
K1 Supervivencia sin enfermedad
K1 Metástasis de la neoplasia
K1 Resultado del tratamiento
AB BACKGROUNDThe optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC.METHODSPatients received intravenous irinotecan 175 mg/m(2) on day 1 and oral capecitabine 1000 mg/m(2) (800 mg/m(2) for patients >65 years of age) twice daily on days 2-8, followed by a 1-week rest, and bevacizumab 5 mg/kg as an intravenous infusion on day 1 every 2 weeks.RESULTSSeventy-seven patients were included in the intention-to-treat and safety populations. Progression-free survival at 9 months was 61%. The overall response and disease control rates were 51% and 84%, respectively. Median progression-free and overall survival times were 11.9 and 24.8 months, respectively. 48 patients (62%) had at least one grade 3/4 adverse event, the most common being asthenia, diarrhoea and neutropenia. Quality of life varied little over the study period with mean visual analogue scale general health scores ranging from 71 to 76 over cycles 1-11.CONCLUSIONOur study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with mCRC to be an effective and tolerable regimen.
PB BioMed Central
YR 2015
FD 2015-04-29
LK http://hdl.handle.net/10668/2218
UL http://hdl.handle.net/10668/2218
LA en
NO Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, et al. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 2015; 15:327
NO TRIAL REGISTRATIONclinicaltrials.gov identifier NCT00875771. Trial registration date: 04/02/2009. Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 9, 2025